Evidence map›Paper›PMID 40692387›Full record

ArticleAngewandte Chemie (International ed. in English)2025

Ligand Type Guided Keto-Arylation Enables Modular Total Synthesis of Polycyclic CBS Xanthones.

Jonas W Meringdal, Vivienne Prangenberg, Tim Treiber, Andreas J Schneider, Leon Honsdorf, Dirk Menche

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jonas W MeringdalKekulé-Institute for Organic Chemistry and Biochemistry, University of Bonn, Gerhard-Domagk-Str. 1, 53121, Bonn, Germany.ORCID https://orcid.org/0009-0003-6528-2731
Vivienne PrangenbergKekulé-Institute for Organic Chemistry and Biochemistry, University of Bonn, Gerhard-Domagk-Str. 1, 53121, Bonn, Germany.
Tim TreiberKekulé-Institute for Organic Chemistry and Biochemistry, University of Bonn, Gerhard-Domagk-Str. 1, 53121, Bonn, Germany.
Andreas J SchneiderKekulé-Institute for Organic Chemistry and Biochemistry, University of Bonn, Gerhard-Domagk-Str. 1, 53121, Bonn, Germany.
Leon HonsdorfKekulé-Institute for Organic Chemistry and Biochemistry, University of Bonn, Gerhard-Domagk-Str. 1, 53121, Bonn, Germany.
Dirk MencheKekulé-Institute for Organic Chemistry and Biochemistry, University of Bonn, Gerhard-Domagk-Str. 1, 53121, Bonn, Germany.ORCID https://orcid.org/0000-0002-4724-8383

Funding

Deutsche Forschungsgemeinschaft GRK 2873
6 · The paper itself

Abstract

The first total synthesis of the potent polycyclic xanthone antibiotics CBS72, CBS87 and CBS100 was accomplished by a modular strategy featuring a very demanding intermolecular aromatic keto-arylation. Central to the solution was a recently-developed ligand type approach, rather than brute force screening, demonstrating the usefulness of this novel concept in complex target synthesis. Additional key features include an asymmetric Davis hydroxylation proceeding with only catalytic amounts of base, thus enabling the conversion of a highly sensitive, elaborate substrate. Furthermore, a late-stage aminolysis completed the polycyclic framework, circumventing laborious protective group chemistry. Together, this strategy provides a concise, high-yielding access, confirming the full architecture of this most potent class of polyaromatic xanthones, and establishes ligand types as a powerful design tool for sophisticated cross-couplings.

Indexed as

Davis oxidationKeto‐arylationLigand typesPolycyclic xanthonesTotal synthesis

Identifiers

PMID40692387
PMCPMC12416469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.